Main Article Content
Type II diabetes mellitus, Vildagliptin, Pioglitazone, efficacy, safety
Background: Diabetes mellitus type II (DM) is a chronic metabolic condition characterized by insulin resistance and decreased insulin production. In patients with type II diabetes, the combination of pioglitazone and vildagliptin has been demonstrated to enhance glycemic control. However, studies investigating the effectiveness and safety of this combination treatment in the real-world setting are insufficient.
Objectives: this retrospective study was to assess the effectiveness and safety of vildagliptin when used as supplementary treatment with pioglitazone for patients diagnosed with type II diabetes mellitus
Study design: A Retrospective Study
Duration and place of study: department of medicine mmc mardan from jan 2022 to jan 2023
Methods: The study comprised 65 patients who received a combination therapy of vildagliptin/pioglitazone at either a high dosage of 100/30 mg once daily (n=35) or a low dose of 50/15 mg once daily (n=30). Additionally, some patients received monotherapy with either vildagliptin at 100 mg once daily (n=33) or pioglitazone at 30 mg once daily (n=32). The secondary objectives included changes in fasting plasma glucose (FPG) concentrations, body weight, and any adverse events.
The study included 65 patients, 56.9% males and 43.07% females. The average age of the participants was 58.5 years, ranging from 16 to 75 years. 11 common adverse events were observed, the most common of which was nasopharyngitis (4.6%). Dizziness, headache, upper respiratory tract infection, asthenia, and constipation were all typical side effects. Vildagliptin/Pioglitazone 100/30 mg once daily (n=35), 50/15 mg (n=30), 100 mg Vildagliptin (n=33), and 30 mg Pioglitazone (n=32) were used in the study. For glycemic control, baseline HbA1c levels ranged from 8.2% in the Vildagliptin/Pioglitazone 100/30 mg group to 8.9% in the 30 mg group. At baseline, fasting plasma glucose (FPG) levels varied from 9.2 mmol/L in the Vildagliptin/Pioglitazone 100/30 mg group to 10.3 mmol/L in the 50/15 mg group. T2DM lasted 3.5-4.2 years in all participants.
Conclusion: Incorporating vildagliptin into pioglitazone treatment among patients diagnosed with type II diabetes mellitus led to notable enhancements in glycemic regulation while exhibiting no substantial alterations in body weight. The combination therapy demonstrated favorable tolerability and may be considered a viable and secure therapeutic approach for those diagnosed with type II diabetes mellitus.
2. Iciar Martín-Timón, Cristina Sevillano-Collantes, Amparo Segura-Galindo, and Francisco Javier del Cañizo-Gómez, Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?, 2014 Aug 15; 5(4): 444–470. doi: 10.4239/wjd.v5.i4.444.
3. Arun Chaudhury, Chitharanjan Duvoor, Vijaya Sena, Reddy Dendi, Shashank Kraleti, Aditya Chada, Rahul Ravilla, Asween Marco, Nawal Singh, Shekhawat, Maria Theresa Montales, Kevin Kuriakose , Appalanaidu Sasap, Alexandria Beebe, Naveen Patil, Chaitanya K. Musham, Govinda, Prasad Lohan, Wasique Mirza, Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management, 24 January 2017. doi.org/10.3389/fendo.2017.00006.
4. Dídac Mauricio, Luigi MeneghiniD, Jochen Seufert , Laura Liao, Hongwei Wang, Liyue Tong, Anna Cali, Peter Stella, Paulo Carita, Kamlesh Khunti, Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA, 02 March 2017. doi.org/10.1111/dom.12927.
5. Abbas, Aamer; Blandon, Jimena; Rude, Jennifer; Elfar, Ahmed; Mukherjee, Debabrata, PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations, 2012, pp. 124-134(11). doi.org/10.2174/187152512800388948.
6. Bolen S, Feldman L, Vassy J, Wilson L, Yeh H, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass ER, Brancati F: Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399, 2007.
7. Bancha Satirapoj ,Khanin Watanakijthavonkul,Ouppatham Supasyndh, Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial, October 31, 2018. doi.org/10.1371/journal.pone.0206722.
8. C.K. Chakraborti, The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus, 2008 Jan-Feb; 40(1): 10–14.. doi: 10.4103/0253-7613.40482.
9. John M Stafford1 and Tom Elasy, Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes, 2007 Aug; 3(4): 503–510.
10. Israili, Zafar H, Advances in the Treatment of Type 2 Diabetes Mellitus, American Journal of Therapeutics 18(2):p 117-152, March 2011. | DOI: 10.1097/MJT.0b013e3181afbf51.
11. Lorraine Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Lori MacCallum, Baiju R. Shah, Scot Simpson, Peter A, Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update, October 2020, Pages 575-591, doi.org/10.1016/j.jcjd.2020.08.001.
12. Melanie J. Davies; David A. D’Alessio; Judith Fradkin; Walter N. Kernan; Chantal Mathieu, Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. 2018;41(12):2669–2701. doi.org/10.2337/dci18-0033.
13. N. Suksomboon, N. Poolsup A. Yuwanakorn , Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes, 17 March 2014. doi.org/10.1111/jcpt.12147.
14. Chantal Mathieu & Evy Degrande, Vildagliptin: a new oral treatment for type 2 diabetes mellitus. 26 Dec 2022, Pages 1349-1360. doi.org/10.2147/vhrm.s3005.
15. Mahalingam Balakumar, Durai Prabhu, Chandrakumar Sathishkumar, Paramasivam Prabu, Namita Rokana, Ramesh Kumar, Srividhya Raghavan, Avinash Soundarajan, Sunita Grover, Virender Kumar Batish, Viswanathan Mohan & Muthuswamy Balasubramanyam, Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice, Published: 18 October 2016, 57, pages279–295.
16. M. Ligueros-Saylan, J. E. Foley, A. Schweizer, A. Couturier, W. Kothny, An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials, 20 April 2010. doi.org/10.1111/j.1463-1326.2010.01214.x.